BioAtla is extending its runway beyond key clinical readouts in 1H 2026 by restructuring and realigning resources, which ...

Radiopharm Theranostics Limited targets oncology with radiotherapeutics like Lu-RAD204 for NSCLC. Key 2025 data signals ...

Exelixis, Inc. EXEL announced that the FDA has approved the label expansion of its lead drug Cabometyx (cabozantinib). The ...

The Japanese Ministry of Health, Labour and Welfare on Thursday approved Genmab A/S’ (NASDAQ:GMAB) Tivdak (tisotumab vedotin) ...

Drug development is coming back in vogue and this fund’s ‘full life cycle’ approach means it’s ready to capture the gains ...

Bioconjugation presents an new frontier for pharmaceutical development, providing an option for improved drug efficacy across ...

Deloitte urged pharma executives to “be bold” in a new report tracking the top 20 pharmaceutical companies’ R&D performance.

A group of researchers from the Pohang University of Science and Technology Department of Materials Science and Engineering, under the direction of Professor Seung Soo Oh and Dr. Hyesung Jo, have ...

SUZHOU, China, March 27, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a biopharmaceutical company dedicated to developing innovative cancer therapies, today reported 2024 annual ...

NEW YORK - On Thursday, ADC Therapeutics SA (NYSE: ADCT) reported fourth quarter financial results that beat earnings expectations but fell short on revenue. The company’s stock was unchanged in after ...

GlycoNex, Inc. (4168, hereinafter referred to as GNX), a clinical stage biotechnology company focused on the development of glycan-directed cancer immunotherapies, today announced that preclinical ...

Johnson & Johnson has been saying for some time that it thinks its combination of Rybrevant and Lazcluze is the best option for patients with EGFR-mutated non-small cell lung cancer (NSCLC) – and now ...